Oppenheimer & Co’s Intellia Therapeutics NTLA Stock Holding History

Oppenheimer & Co’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.32M	Buy	109,862 +2,409	+2%	+$30.1K	0.01%	799
2026 Q2	$1.82M	Buy	107,453 +529	+0.5%	+$7.4K	0.02%	676
2026 Q1	$1.37M	Buy	106,924 +1,759	+2%	+$22.4K	0.02%	732
2025 Q4	$945K	Buy	105,165 +808	+0.8%	+$11.1K	0.01%	822
2025 Q3	$1.8M	Sell	104,357 -1,857	-2%	-$22.9K	0.02%	646
2025 Q2	$996K	Buy	106,214 +87,506	+468%	+$719K	0.01%	855
2025 Q1	$133K	Buy	18,708 +823	+5%	+$8.31K	﹤0.01%	1500
2024 Q4	$209K	Buy	+17,885	New	+$279K	﹤0.01%	1438
2023 Q4	–	Sell	-7,810	Closed	-$247K	–	1436
2023 Q3	$247K	Sell	7,810 -372	-5%	-$14.4K	0.01%	1199
2023 Q2	$334K	Buy	+8,182	New	+$332K	0.01%	1127
2021 Q4	–	Sell	-1,824	Closed	-$245K	–	1538
2021 Q3	$245K	Sell	1,824 -447	-20%	-$67.7K	﹤0.01%	1306
2021 Q2	$368K	Buy	+2,271	New	+$177K	0.01%	1153

Other funds holding NTLA

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $180M AUM 18.92% 1-Year Est. Return

Nikko Asset Management Americas New York $8.04B AUM 33.34% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Oppenheimer & Co's NTLA Position: Q3 2026 in Review

Oppenheimer & Co increased its Intellia Therapeutics (NTLA) stake by 2.2% in Q3 2026, buying an estimated $30.1K and bringing the position to 109,862 shares worth $1.32M. The position accounts for 0.01% of the portfolio, ranked #799.

Oppenheimer & Co first reported a position in NTLA in Q2 2021 and has held it in 12 quarters since. The position peaked at $1.82M in Q2 2026. 239 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

Oppenheimer & Co held 109,862 shares of Intellia Therapeutics worth $1.32M as of Q3 2026.
Oppenheimer & Co bought 2,409 Intellia Therapeutics shares in Q3 2026, an estimated $30.1K.
Intellia Therapeutics made up 0.01% of Oppenheimer & Co's portfolio in Q3 2026, its #799 holding.
Oppenheimer & Co first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 12 quarters since.
Oppenheimer & Co's Intellia Therapeutics position peaked at $1.82M in Q2 2026.
239 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on Oppenheimer & Co's 13F filing for Q3 2026, filed 26 Oct 2026.